|Table of Contents|

Research progress of insights into the molecular mechanisms of m6A modification of ferroptosis in cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 24
Page:
4640-4645
Research Field:
Publishing date:

Info

Title:
Research progress of insights into the molecular mechanisms of m6A modification of ferroptosis in cancer
Author(s):
LI Tianzhu1; 2; HAO Dandan2; 3
1.Molecular Medicine Research Center,School of Basic Medical Science,Chifeng University,Inner Mongolia Chifeng 024000,China；2.Key Laboratory of Research on Human Genetic Diseases at Universities of Inner Mongolia Autonomous Region,Inner Mongolia Chifeng 0
Keywords:
cancer; ferroptosis; epigenetic modifications; N6-methyladenosine modification
PACS:
R730
DOI:
10.3969/j.issn.1672-4992.2023.24.031
Abstract:
Ferroptosis,an unique modality of cell death that is mechanistically and morphologically different from other forms of cell death,plays a pivotal role in regulating tumor growth and has presented a new opportunity for chemotherapy resistance.Dysregulated epigenetic modifications dynamically drive the abnormal transcription process to promote cancer drug resistance,progression,and metastasis.The accumulating studies indicate that epigenetic modification by m6A can regulate ferroptosis in cancer.In the present review article,we firstly briefly summarize the core molecular mechanisms of ferroptosis.Then the role of epigenetic processes,i.e.m6A modification is concisely discussed,followed by describing the role of m6A modification on ferroptosis in detail in the genesis of cancer.

References:

[1] STOCKWELL BR.Ferroptosis turns 10:Emerging mechanisms,physiological functions,and therapeutic applications［J］.Cell,2022,185(14):2401-2421.
[2] STOCKWELL BR,FRIEDMANN ANGELI JP,BAYIR H,et al.Ferroptosis:a regulated cell death nexus linking metabolism,redox biology,and disease［J］.Cell,2017,171(2):273-285.
[3] WANG Y,WU X,REN Z,et al.Overcoming cancer chemotherapy resistance by the induction of ferroptosis［J］.Drug Resistance Updates:Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy,2023,66:100916.
[4] CHEN X,KANG R,KROEMER G,et al.Organelle-specific regulation of ferroptosis［J］.Cell Death and Differentiation,2021,28(10):2843-2856.
[5] TANG D,CHEN X,KANG R,et al.Ferroptosis:molecular mechanisms and health implications［J］.Cell Research,2021,31(2):107-125.
[6] TANG D,KROEMER G.Ferroptosis［J］.Current Biology:CB,2020,30(21):R1292-R1297.
[7] CHEN X,KANG R,KROEMER G,et al.Ferroptosis in infection,inflammation,and immunity［J］.The Journal of Experimental Medicine,2021，218(6):e20210518..
[8] LEI G,ZHUANG L,GAN B.Targeting ferroptosis as a vulnerability in cancer［J］.Nature Reviews.Cancer,2022,22(7):381-396.
[9] LEI G,MAO C,YAN Y,et al.Ferroptosis,radiotherapy,and combination therapeutic strategies［J］.Protein & Cell,2021,12(11):836-857.
[10] GUO J,XU B,HAN Q,et al.Ferroptosis:a novel anti-tumor action for cisplatin［J］.Cancer Research and Treatment,2018,50(2):445-460.
[11] CHEN X,KANG R,KROEMER G,et al.Broadening horizons:the role of ferroptosis in cancer［J］.Nature Reviews.Clinical oncology,2021,18(5):280-296.
[12] ZHANG C,LIU X,JIN S,et al.Ferroptosis in cancer therapy:a novel approach to reversing drug resistance［J］.Molecular Cancer,2022,21(1):47.
[13] 庞敬瑶，李佩玲,BEILERLI AFERIN,等.基于铁死亡的癌症治疗新策略［J］.现代肿瘤医学，2021,29(06):1058-1061. PANG Jingyao,LI Peiling,BEILERLI AFERIN,et al.New strategies of cancer therapy based on ferroptosi［J］.Modern Oncology,2021,29(06):1058-1061.
[14] NIKOLAOU M,PAVLOPOULOU A,GEORGAKILAS AG,et al.The challenge of drug resistance in cancer treatment:a current overview［J］.Clinical & Experimental Metastasis,2018,35(4):309-318.
[15] MARINE JC,DAWSON SJ,DAWSON MA.Non-genetic mechanisms of therapeutic resistance in cancer［J］.Nature Reviews.Cancer,2020,20(12):743-756.
[16] GOTTESMAN MM.Mechanisms of cancer drug resistance［J］.Annual Review of Medicine,2002,53:615-627.
[17] GONZALEZ-MOLINA J,MOYANO-GALCERAN L,SINGLE A,et al.Chemotherapy as a regulator of extracellular matrix-cell communication:Implications in therapy resistance［J］.Seminars in Cancer Biology,2022,86(Pt 3):224-236.
[18] NIE Z,CHEN M,GAO Y,et al.Ferroptosis and tumor drug resistance:current status and major challenges［J］.Frontiers in Pharmacology,2022,13:879317.
[19] 王睿,沙仁高娃.顺铂诱导铁死亡促进肿瘤相关巨噬细胞极化抑制宫颈癌细胞耐药性［J］ 现代肿瘤医学，2022,30(13):2320-2325. WANG Rui,Sharengaowa.Cisplatin-induced ferroptosis promotes tumor-associated macrophage polarization to inhibits drug resistance in cervical cancer cells［J］.Modern Oncology，2022,30(13):2320-2325.
[20] CAVALLI G,HEARD E.Advances in epigenetics link genetics to the environment and disease［J］.Nature,2019,571(7766):489-499.
[21] CAO J,YAN Q.Cancer epigenetics,tumor immunity,and immunotherapy［J］.Trends in Cancer,2020,6(7):580-592.
[22] WANG N,MA T,YU B.Targeting epigenetic regulators to overcome drug resistance in cancers［J］.Signal Transduction and Targeted Therapy,2023,8(1):69.
[23] DENG LJ,DENG WQ,FAN SR,et al.m6A modification:recent advances,anticancer targeted drug discovery and beyond［J］.Molecular Cancer,2022,21(1):52.
[24] ZHUANG H,YU B,TAO D,et al.The role of m6A methylation in therapy resistance in cancer［J］.Molecular Cancer,2023,22(1):91.
[25] 桂佳伟,肖辉.N6-甲基腺嘌呤修饰在恶性肿瘤发生发展及治疗中的研究进展［J］.现代肿瘤医学，2023,31(01):183-187. GUI Jiawei,XIAO Hui.Research progress of N6-methyladenine modification in the occurrence,development and treatment of malignant tumors［J］.Modern Oncology，2023,31(01):183-187.
[26] MA L,CHEN T,ZHANG X,et al.The m6A reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11-dependent antioxidant function［J］.Redox Biology,2021,38:101801.
[27] XU Y,LV D,YAN C,et al.METTL3 promotes lung adenocarcinoma tumor growth and inhibits ferroptosis by stabilizing SLC7A11 m(6)A modification［J］.Cancer Cell International,2022,22(1):11.
[28] SUN S,GAO T,PANG B,et al.RNA binding protein NKAP protects glioblastoma cells from ferroptosis by promoting SLC7A11 mRNA splicing in an m6A-dependent manner［J］.Cell Death & Disease,2022,13(1):73.
[29] LIU L,HE J,SUN G,et al.The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma［J］.Clinical and Translational Medicine,2022,12(5):e778.
[30] JI FH,FU XH,LI GQ,et al.FTO prevents thyroid cancer progression by SLC7A11 m6A methylation in a ferroptosis-dependent manner［J］.Frontiers in Endocrinology,2022,13:857765.
[31] SONG Z,JIA G,MA P,et al.Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis［J］.Life Sciences,2021,276:119399.
[32] YUAN J,LV T,YANG J,et al.HDLBP-stabilized lncFAL inhibits ferroptosis vulnerability by diminishing Trim69-dependent FSP1 degradation in hepatocellular carcinoma［J］.Redox Biology,2022,58:102546.
[33] YE F,WU J,ZHANG F.METTL16 epigenetically enhances GPX4 expression via m6A modification to promote breast cancer progression by inhibiting ferroptosis［J］.Biochemical and Biophysical Research Communications,2023,638:1-6.
[34] XU X,CUI J,WANG H,et al.IGF2BP3 is an essential N6-methyladenosine biotarget for suppressing ferroptosis in lung adenocarcinoma cells［J］.Materials Today.Bio,2022,17:100503.
[35] LU Z,YANG H,SHAO Y,et al.IGF2BP3-NRF2 axis regulates ferroptosis in hepatocellular carcinoma［J］.Biochemical and Biophysical Research Communications,2022,627:103-110.
[36] YE J,CHEN X,JIANG X,et al.RNA demethylase ALKBH5 regulates hypopharyngeal squamous cell carcinoma ferroptosis by posttranscriptionally activating NFE2L2/NRF2 in an m6 A-IGF2BP2-dependent manner［J］.Journal of Clinical Laboratory Analysis,2022,36(7):e24514.
[37] LI W,HUANG G,WEI J,et al.ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1-Nrf2/HO-1 axis［J］.Molecular and Cellular Biochemistry,2023,478(4):729-741.
[38] ZOU Y,ZHENG S,XIE X,et al.N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer［J］.Nature Communications,2022,13(1):2672.
[39] YANG H,HU Y,WENG M,et al.Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer［J］.Journal of Advanced Research,2022,37:91-106.
[40] MA L,ZHANG X,YU K,et al.Targeting SLC3A2 subunit of system X(C)(-) is essential for m6A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma［J］.Free Radical Biology & Medicine,2021,168:25-43.
[41] HUANG WM,LI ZX,WU YH,et al.m6A demethylase FTO renders radioresistance of nasopharyngeal carcinoma via promoting OTUB1-mediated anti-ferroptosis［J］.Translational Oncology,2023,27:101576.
[42] BERSUKER K,HENDRICKS JM,LI Z,et al.The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis［J］.Nature,2019,575:688-692.
[43] DOLL S,FREITAS FP,SHAH R,et al.FSP1 is a glutathione-independent ferroptosis suppressor［J］.Nature,2019,575:693-698.
[44] CUADRADO A,ROJO AI,WELLS G,et al.Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases［J］.Nature Reviews.Drug Discovery,2019,18(4):295-317.
[45] KAJARABILLE N,LATUNDE-DADA GO.Programmed cell-death by ferroptosis:antioxidants as mitigators［J］.International Journal of Molecular Sciences,2019,20(19):4968.
[46] DODSON M,CASTRO-PORTUGUEZ R,ZHANG DD.NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis［J］.Redox Biology,2019,23:101107.
[47] QU Z,SUN J,ZHANG W,et al.Transcription factor NRF2 as a promising therapeutic target for Alzheimer's disease［J］.Free Radical Biology & Medicine,2020,159:87-102.

Memo

Memo:
National Natural Science Foundation of China(No.82060118）；国家自然科学基金项目(编号：82060118)；内蒙古自治区自然科学基金项目(编号：2022MS08032)；内蒙古自治区高等学校科学研究项目(编号：NJZY20203);赤峰学院青年科技英才项目(编号：CFXYYT2202)
Last Update: 1900-01-01